kidney disease

Vertex's cystic fibrosis market dominance faces gene therapy competition post-patent expiration, but patent protection extends through late 2030s while diversification efforts hedge risk.

XORTX acquires Vectus kidney fibrosis asset VB4-P5 for $3M, expanding pipeline in high-potential CKD therapeutics market.

Maze Therapeutics CMO Harold Bernstein sold 15,000 shares (~$442K) via pre-planned trading arrangement. Retains 237K options amid clinical-stage biotech challenges.

XORTX Therapeutics completes 1-for-5 share consolidation effective April 6, 2026, receiving TSX Venture Exchange and Nasdaq approvals. Clinical-stage pharma firm developing gout and kidney disease therapies.

SCYNEXIS completes acquisition of PXL-770 AMPK activator for ADPKD treatment. Deal includes $8M upfront, up to $188M milestones; Phase 2 study planned for late 2026.

American Heart Association launches Cardiovascular-Kidney-Metabolic initiative to address interconnected diseases affecting 90% of U.S. adults, emphasizing screening and prevention.

Novartis' Fabhalta slowed kidney function decline by 49.3% in Phase III trial, with FDA priority review granted for IgA nephropathy treatment.

XORTX Therapeutics shareholders approved all proposals at March 24 meeting with 35% representation, including new leadership and share consolidation.

Vertex Pharmaceuticals trails broader market but boasts promising pipeline candidates in kidney disease and diabetes, positioning potential recovery.

XORTX shareholders approved a 5-to-1 share consolidation to maintain NASDAQ compliance, reducing shares from 6.96M to 1.39M ahead of April 2026 deadline.

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.

Deerfield Management increases Vera Therapeutics stake to $205.58M as kidney drug atacicept approaches July 7 FDA decision. Stock up 50% annually.

XORTX Therapeutics secures ISS endorsement for share consolidation, with proxy advisor backing March 2026 shareholder vote. ISS cited no direct shareholder value impact while noting improved financing prospects.

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.

Akebia Therapeutics will release 2025 financial results February 26, 2026, followed by a conference call discussing operational performance and strategic updates.

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.